CEA-Scan to get February review:
This article was originally published in Clinica
The US FDA's Medical Imaging Drugs Advisory Committee (MIDAC) plans to review Immunomedics' CEA-Scan on February 16th. The Oncologic Drugs Advisory Committee deferred a decision on the colon-cancer imaging agent in October, saying MIDAC was a more relevant body to review the data (see Clinica No 678, p 19). The committee also criticised a lack of outcomes data and a failure to blind several investigators.